Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.
Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.
Key updates cover:
• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications
Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.
CureVac has announced updates on its ongoing patent litigation against Pfizer/BioNTech across the U.S., UK, and Germany. A U.S. trial date has been set for March 3, 2025, following a settlement with Acuitas Therapeutics that led to the withdrawal of three disputed patents. In Europe, the European Patent Office will decide on the validity of EP 3 708 668 B1 on March 25, 2025. German litigation sees a hearing scheduled in Düsseldorf on September 10, 2024. Meanwhile, a UK trial began on July 10, 2024, with a judgement expected later this year. These litigations involve patents related to split poly-A tail technology and COVID-19 vaccine design.
Agomab Therapeutics NV has appointed Pierre Kemula as its new Chief Financial Officer, effective November 1, 2024. Mr. Kemula joins from CureVac N.V. (Nasdaq: CVAC), where he led significant financial achievements, including a successful Nasdaq listing and raising over $1.6 billion in equity. He will replace Tolga Hassan, who recently departed to explore new opportunities. During the transition, Paul van der Horst has been serving as interim CFO. Agomab CEO Tim Knotnerus expressed confidence in Kemula’s expertise to drive the company’s growth. Kemula brings over 15 years of experience in biotech financial leadership, with previous roles at Pixium Vision, Ipsen, and major consulting firms.
CureVac has announced a strategic restructuring to focus on high-value mRNA pipeline opportunities, particularly in oncology and other critical diseases. This includes a 30% workforce reduction to create a leaner organization, emphasizing research and development. The company aims to deliver two clinical candidates by the end of 2025 and initiate two new Phase 1 studies by the end of 2026. A recent licensing agreement with GSK, worth up to €1.45 billion plus royalties, will extend CureVac's cash runway into 2028. Operational expenses are expected to decrease by over 30% from 2025, with one-time restructuring charges of approximately €15 million anticipated in Q4 2024.
GSK and CureVac have restructured their existing collaboration into a new licensing agreement. GSK will acquire full rights to develop, manufacture, and commercialize mRNA candidate vaccines for influenza and COVID-19 globally. CureVac will receive an upfront payment of €400 million, and up to an additional €1.05 billion in milestone payments, along with tiered royalties. This new agreement supersedes any previous financial terms from their prior collaboration. The candidate vaccines are in various stages of clinical development and utilize CureVac's second-generation mRNA technology. GSK aims to leverage its capabilities to advance these vaccines, while CureVac retains rights to develop other mRNA vaccines independently. The agreement is subject to antitrust and regulatory approvals.
CureVac N.V. (NASDAQ:CVAC), a clinical-stage biopharmaceutical company specializing in mRNA-based medicines, announced the voting results of its annual general meeting held on June 24, 2024. Shareholders approved all proposed motions, including the appointment of Thaminda Ramanayake and the reappointment of Malte Greune to the Management Board. Additionally, Jean Stéphenne and Mathias Hothum were reappointed to the Supervisory Board, while Birgit Hofmann was appointed as a new Supervisory Board member. KPMG Accountants N.V. was reappointed as the external auditors for the financial year 2024. Detailed vote tabulations will be released soon.
CureVac has commenced dosing of the first participant in a Phase 2 study for its multivalent seasonal influenza vaccine candidate, developed in collaboration with GSK. This follows interim data from a Phase 2 part of a combined Phase 1/2 study, which showed the vaccine candidate elicited stronger immune responses against influenza A strains but weaker responses against influenza B strains compared to licensed vaccines. The Phase 2 study's design has been updated to match the three flu strains recommended by the WHO, excluding the B/Yamagata lineage. The study will evaluate the safety, reactogenicity, and immunogenicity of the vaccine in 500 healthy adults, split between younger (18-64) and older (65-85) participants.
CureVac (Nasdaq: CVAC) has announced its Q1 2024 financial results and business updates.
The company is in the process of an organizational redesign, reducing 150 positions by year-end to trim pandemic infrastructure and increase efficiency.
CureVac's pre-pandemic H5N1 vaccine, co-developed with GSK, received FDA Fast Track designation and is in Phase 1 development.
Settlements with Acuitas Therapeutics recognized CureVac’s patent claims, while ongoing litigation with Pfizer/BioNTech continues under seven U.S. patents, with a trial set for Q2 2025.
In Q1 2024, CureVac reported €300.2 million in cash, €12.4 million in revenue (up 74% YoY), and an operating loss of €73.3 million.
FAQ
What is the current stock price of Curevac B.V. (CVAC)?
What is the market cap of Curevac B.V. (CVAC)?
